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Abstract
AKT1 (NP_005154.2) is a member of the serine/threonine AGC protein kinase family involved in cellular metabolism, growth,
proliferation and survival. The three human AKT isozymes are highly homologous multi-domain proteins with both
overlapping and distinct cellular functions. Dysregulation of the AKT pathway has been identified in multiple human
cancers. Several clinical trials are in progress to test the efficacy of AKT pathway inhibitors in treating cancer. Recently, a
series of AKT isozyme-selective allosteric inhibitors have been reported. They require the presence of both the pleckstrin-
homology (PH) and kinase domains of AKT, but their binding mode has not yet been elucidated. We present here a 2.7 A ˚
resolution co-crystal structure of human AKT1 containing both the PH and kinase domains with a selective allosteric
inhibitor bound in the interface. The structure reveals the interactions between the PH and kinase domains, as well as the
critical amino residues that mediate binding of the inhibitor to AKT1. Our work also reveals an intricate balance in the
enzymatic regulation of AKT, where the PH domain appears to lock the kinase in an inactive conformation and the kinase
domain disrupts the phospholipid binding site of the PH domain. This information advances our knowledge in AKT1
structure and regulation, thereby providing a structural foundation for interpreting the effects of different classes of AKT
inhibitors and designing selective ones.
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Introduction
Aberrant regulation of the PI3K/AKT pathway is implicated in the
pathogenesis of several human cancers and inhibitors for multiple
targets in this pathway are in clinical trials for the treatment of cancer
[1]. There are three isozymes of human AKT (AKT1, 2, and 3, also
known as PKB-a,- b and -c), each containing an amino (N)-terminal
PH domain, inter-domain linker, kinase domain and 21-residue
carboxy (C)-terminal hydrophobic motif (HM) [2,3]. The PH domain
directs AKT translocation from the cytosol to the plasma mem-
brane by binding to the membrane lipids phosphatidylinositide
(PtdIns)(3,4)P2 and PtdIns(3,4,5)P3, which are products of phospha-
tidylinositide-3-kinase (PI3K). AKT is subsequently phosphorylated
resulting in kinase activation [4]. Due to the tractability of kinases as
pharmacological targets and the observed hyperactivation of AKT in
many cancers, several small molecule inhibitors of AKT have been
described (recently reviewed [5]). The majority of described AKT
inhibitors are competitive with ATP, non-selective against AKT
isozymes, and poorly selective against closely related kinases. Efforts to
identify AKT specific and isozyme-selective inhibitors resulted in the
discovery of novel selective, allosteric AKT inhibitors [6,7]. As only a
few kinases have been reported to be allosterically inhibited by small
molecules [8,9,10], further investigation into the requirements for
allosteric AKT inhibition was undertaken. Intriguingly, a new
allosteric inhibition paradigm was revealed in which the presence of
both the regulatory PH domain and catalytic kinase domain were
required for allosteric inhibition. Subsequently the allosteric AKT
inhibitors were optimized for clinical use and recently one, MK-2206,
was reported to be well-tolerated in a Phase I clinical trial [11].
Comprehensive and elegant experimentation revealed substantial
differences in the relative positions of the PH and kinase domains of
inactive and membrane-associated AKT [12,13,14,15,16], resulting
i nt h ei n a c t i v ef o r mb e i n gt e r m e dt h ec l o s e do r‘ P H - i n ’c o n f o r m a t i o n ;
whereas the membrane-associated form is referred to as the open or
‘PH-out’ conformation. More in-depth characterization of Inhibitor
VIII (Figure 1), a commercially available PH domain-dependent
allosteric AKT1/2 inhibitor (Compound 16 h) [7], showed that
Inhibitor VIII is dependent upon the presence of Trp 80 in the PH
domain for its activity; and the inhibitor binds to a generally
characterized ‘PH-in’ conformation of AKT1 [15,17]. Therefore, in
order to further our understanding of the regulation and inhibition of
AKT and to aid in the design of selective AKT inhibitors, we
extensively screened for crystals of AKT complexed to an allosteric
inhibitor.Herewe reportthe crystal structure of AKT1 complexed to
Inhibitor VIII at 2.7 A ˚ resolution (PDB code: 3O96).
Results
We expressed, purified, and set-up crystallization screens of full-
length AKT1 and AKT2 pre-incubated with Inhibitor VIII. After
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e129132.5 months, we observed a single small crystal in a full-length
AKT1 crystal screen and determined from initial diffraction
patterns that the crystal was proteinaceous. After the long time
required for crystal growth, concern that the protein was
proteolyzed in the crystallization drop arose, so the crystal was
analyzed by sodium dodecyl sulphate (SDS)-polyacrylamide gel
electrophoresis. We observed two major truncated forms of AKT1
protein from the crystal including one which was approximately
6,000 Daltons (Da) smaller than the starting material (Figure S1).
We hypothesized that the most likely region for proteolysis
resulting in a 50 kDa fragment would be in the disordered region
encompassing the C-terminal HM segment. Therefore several
carboxy-terminal truncated AKT1 (DHM-AKT1) constructs were
expressed to identify a modestly truncated form suitable for
crystallographic studies. DHM-AKT1(1-443) was successfully
purified and its binding to Inhibitor VIII was analyzed using
differential scanning fluorimetry [18] (Figure S2). We were able to
co-crystallize DHM-AKT1(1–443) with Inhibitor VIII and to solve
its structure to 2.7 A ˚ resolution (Table 1 and Figure 2).
Figure 3 shows the overall structure of the allosterically inhibited
enzyme. The PH domain nestles between the N- and C-lobes of
the kinase domain with Inhibitor VIII binding to all three regions.
The conformation of the PH domain is similar to the previously
determined apo structure [19] (RMSD=1.14 A ˚ for all Ca’s) with
significant conformational differences in the regions binding to the
inhibitor and kinase domain described below. Both lobes of the
Figure 1. Schematic structure of the AKT1/2 inhibitor. Inhibitor
VIII (EMD Chemicals) has IC50’s of 58 nM, 210 nM, and 2119 nM against
AKT1, -2, and -3, respectively [7].
doi:10.1371/journal.pone.0012913.g001
Table 1. Data collection and refinement statistics for
AKT1:Inhibitor VIII.
Data collection
Space group P21
Cell dimensions
a, b, c (A ˚) 49.31, 69.94, 61.85
a, b, c (u) 90.0, 100.6, 90.0
Resolution (A ˚) 25 – 2.7 (2.85 – 2.70) *
Rmerge 0.078 (0.382)
I /sI 8.1 (2.0)
Completeness (%) 99.9 (99.9)
Redundancy 3.5 (3.5)
Refinement
Resolution (A ˚) 25 – 2.7 (2.78–2.7)
No. reflections 11,464 (935)
Rwork/Rfree 0.245/0.307 (0.323/0.382)
No. atoms 3,095
Protein 3,032
Ligand/ion 42
Water 21
Average B-factor 52.4
R.m.s. deviations
Bond lengths (A ˚) 0.005
Bond angles (u) 0.88
The dataset was collected on one single crystal.
*Highest resolution shell is shown in parentheses.
doi:10.1371/journal.pone.0012913.t001
Figure 2. Stereo view of the allosteric Inhibitor VIII binding site. Inhibitor VIII is shown in green and Trp 80 is shown in orange.
doi:10.1371/journal.pone.0012913.g002
AKT1:Allosteric Inhibitor
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unphosphorylated structure of AKT2 kinase domain [16]: residues
189–198 of the aC-helix and residues 299–312 of the activation
loop are disordered, while the side chain of Phe 293 blocks the
ATP binding site. In Figure 4 the complex structure of activated
AKT1 kinase domain and an ATP-competitive inhibitor is
superposed upon the co-crystal structure of inactive AKT1:Inhi-
bitor VIII [20] illustrating not only the structural differences
between the N-lobes of the kinase domain and Phe 293 positions,
but also the .10 A ˚ distance between inhibitor binding sites. The
superimposed structures show the PH domain fills part of the
space occupied by the aC-helix and phosphorylated activation
loop in the activated AKT kinase domain structures [20,21];
thereby sterically preventing the kinase domain from attaining an
active conformation. Interactions between the PH domain and the
kinase domain are concentrated in two regions of the kinase
domain – in the N-lobe adjacent to the ATP-binding cleft and in
the C-lobe (Figure 5A). The PH domain buries 1,526 A ˚ 2 of its
surface in this complex and a combination of hydrogen bonds and
nonpolar interactions are observed in both regions of this
interface.
Inhibitor VIII binds to AKT1 in an allosteric binding site
formed at the combined interface of the PH domain and the N-
and C- lobes of the kinase domain. We were pleased to observe a
Figure 3. Crystal structure of Inhibitor VIII bound to AKT1(1–443). (A) Schematic representation showing the orientation of the PH domain
(orange) relative to the N-lobe (pink) and C-lobe (yellow) of the kinase domain and Inhibitor VIII shown in green. (PDB code: 3O96). (B) In the same
orientation as Panel A, the kinase domain is surface rendered. (C) Structure of AKT1(1–443):Inhibitor VIII rotated approximately 180u compared to
Panel B.
doi:10.1371/journal.pone.0012913.g003
Figure 4. Comparison of AKT1 allosteric and ATP competitive inhibitor binding sites. (A) Superposition of AKT1 bound to Inhibitor VIII
and activated AKT1 kinase domain bound to an ATP-competitive inhibitor (PDB code: 3CQW). In the allosteric inhibitor structure, the PH domain is
shown as an orange surface, the kinase domain as a yellow cartoon, and Inhibitor VIII as green sticks. The activated kinase domain is colored blue and
the ATP-competitive inhibitor is shown as magenta sticks. (B) Close-up view of the inhibitor binding positions. AKT1:Inhibitor VIII are representeda si n
Panel A. The ATP-competitive inhibitor and Phe 293 from PDB code 3CQW are shown in magenta. The DFG loop including Phe 293 from the Inhibitor
VIII complex structure are colored green. Note the divergent positions of Phe 293 between the two structures and their superposition onto the
converse inhibitor binding site. For clarity, the activated AKT1 protein backbone trace has been omitted from this panel.
doi:10.1371/journal.pone.0012913.g004
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(Figure 5B) as an alanine mutation of this residue in AKT1 has
been shown to render Inhibitor VIII inactive [15,17]. The position
of Trp 80 in the inhibitor bound structure differs significantly from
both the apo and Ins(1,3,4,5)P4 (IP4) bound PH domain structures,
with an a-carbon displacement of 3.7 A ˚ and 5.3 A ˚, respectively
(Figure S3) indicating the variable loop 3 (VL3) loop shifts to
accommodate various ligands. As shown in Figure 5B and Figure
S4, Inhibitor VIII has several hydrophobic contacts with AKT1
that appear to drive compound binding while only a limited
number of polar contacts are observed.
In the process of discovering Inhibitor VIII, modifications to the
imidazoquinoxaline were found to impact AKT isozyme activity
and selectivity [22]. Therefore, we mapped the amino acid
differences between isozymes on the AKT1:Inhibitor VIII
structure (Figure 6A) and identified only two regions of amino
acid divergence. Both regions are located in the kinase domain
and in the binding site for the tricyclic core. As shown in Figure 6B,
Ser 205 has the only direct hydrogen bond to Inhibitor VIII. In
AKT2 and AKT3, the corresponding residue is threonine. The
second region consists of a three residue turn in AKT1 containing
Glu 267, Lys 268, and Asn 269. This turn is not only one residue
shorter in both AKT2 and AKT3 but the amino acids differ
between isozymes. As illustrated in Figure 6B, this region is located
on the opposite side of the tricyclic system from Trp 80. In
addition to interacting with Inhibitor VIII, Lys 268 also has a
polar interaction with the non-conserved binding site residue Ser
205. The IC50’s for Inhibitor VIII are 58 nM, 210 nM, and
2119 nM for AKT1, AKT2, and AKT3, respectively [7]. As the
majority of residues contacting Inhibitor VIII are conserved
between isozymes, the approximately 35-fold difference in the
inhibitor’s activity between AKT1, and AKT3 are hypothesized to
be due to the amino acid differences at the back of the pocket near
the imidazole on the quinoxaline core. In AKT3, substitution of a
threonine residue for serine at position 203 (equivalent to AKT1
Ser 205) may affect the ability of Inhibitor VIII to hydrogen bond
to the protein and also alters the binding pocket by introducing an
additional methyl group. Deletion of a turn residue in AKT3
located below Inhibitor VIII (corresponding to AKT1 Asn 269) is
expected to change the position of the positively charged Lys
residue so that it no longer interacts with Thr 203 (equivalent to
AKT1 Ser 205) and to change the dimensions of the binding
pocket. Therefore, the AKT1:Inhibitor VIII complex structure
suggests further efforts to design AKT1 selective inhibitors should
focus on optimizing specific interactions with Ser 205 and the Lys
268 loop.
An early regulatory step in the activation of AKT is its
recruitment to the plasma membrane following interaction of the
PH domain with the PI3K products, PtdIns-(3,4,5)P3 and
PtdIns(3,4)P2. We noticed significant conformational and polar
interactions differences in the PH domain when comparing the
allosterically inhibited structure to the IP4 bound crystal structures
(Figure 7). In the multi-domain AKT1 structure, the IP4 binding
site is both rearranged and blocked by the C-lobe of the kinase
domain. The most dramatic difference is observed for Asn 53 and
the surrounding loop of residues 49-55 (Figure 7A). This major
structural change appears to be the result of multiple interactions
between the PH and kinase domains and may be partially
stabilized by the presence of Inhibitor VIII. The network of inter-
domain contacts and extensive rearrangement in and near the IP4
binding site illustrates why the allosterically inhibited ‘PH-in’
conformation does not bind PtdIns(3,4)P2 or PtdIns(3,4,5)P3
(Figure S5).
The transforming somatic mutation of Glu 17 to lysine (E17K)
in AKT1 has been reported in several cancers including human
breast, colorectal, ovarian and endometrial cancers [23].
AKT1(E17K) constitutively associates with the plasma membrane
[23]. Lipid binding studies indicate the mutant’s binding affinity
Figure 5. AKT1 inter-domain and Inhibitor VIII interactions. Close-up views of interaction regions for the PH domain (orange), kinase domain
(yellow), and Inhibitor VIII (green). (A) Interactions between PH and kinase domains. The PH domain residues interacting with the kinase domain are
shown in magenta and the reciprocally binding kinase domain residues are colored cyan. Shown in sticks are two ATP binding residues in the kinase
domain interacting with residues from the PH domain. (B) AKT1 residues interacting with Inhibitor VIII. Interacting residues from the PH (magenta)
and kinase (cyan) domains are labeled. Shown with a dotted line is the lone direct hydrogen bond between the inhibitor and protein.
doi:10.1371/journal.pone.0012913.g005
AKT1:Allosteric Inhibitor
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PtdIns(4,5)P2, is dramatically tighter than AKT1’s (wt) affinity
possibly due to favorable electrostatic interactions between Lys 17
and PtdIns(4,5)P2 [24]. Inhibitor VIII is reported to be 5-fold less
potent on the E17K mutant of AKT1 than on AKT1(wt),
indicating that Glu 17 either directly interacts with the inhibitor or
affects the conformation required to bind inhibitor. We did not
observe Glu 17 binding to the inhibitor in the co-crystal structure,
however Glu 17 forms a salt bridge with the positively charged
kinase residue Arg 273 (Figure 8) almost certainly providing
additional stabilization to the closed ‘PH-in’ conformation.
Conversely, in AKT1(E17K), the positively charged side chains
of Lys 17 and Arg 273 will not form a stabilizing interaction
between the PH and kinase domains thereby shifting the
equilibrium from the closed, ‘PH-in’ conformation to the open,
‘PH-out’ conformation. Therefore the constitutive plasma mem-
brane localization of AKT1(E17K) appears to be the result of both
an equilibrium shift towards the open ‘PH-out’ form and a change
in lipid selectivity.
Discussion
Both allosteric and ATP-competitive small molecule inhibitors
of AKT are being investigated in preclinical and clinical testing. As
shown in Figure 9, although these inhibitors target the same AKT
kinase family, divergent profiles are reported relative to cellular
localization and phosphorylation status. Remarkably, ATP-
competitive inhibitors were shown to induce hyperphosphoryla-
tion via a membrane-dependent and kinase intrinsic mechanism
[25]. Conversely, the allosteric AKT inhibitors prevent both
membrane association and activation by phosphorylation [6,15].
The conformation of the ATP binding site in the AKT1:Inhibitor
VIII crystal structure clearly shows that the PH-in conformer is
unable to bind ATP or ATP-competitive inhibitors. Not only does
Phe 293 block the site, but critical ATP binding site residues
interact with PH domain residues. Therefore, we hypothesize
ATP-competitive AKT inhibitors are unable to bind the ‘PH-in’
conformer and only bind the membrane-associated and phos-
phorylated ‘PH-out’ form, which has a properly configured ATP
binding site. When the competitive inhibitor occupies the ATP
binding site, we propose that the PH domain cannot fully close
onto the kinase domain and the phospholipid binding site remains
exposed thus enhancing the propensity of AKT to localize to the
membrane. In contrast, the AKT1:Inhibitor VIII co-crystal
structure reveals the allosteric inhibitor locking AKT into a closed
conformation with its phospholipid binding site blocked by the
kinase domain. As a result, allosterically inhibited AKT remains
cytosolic and is not activated via phosphorylation. From a clinical
perspective, determining whether these two distinct mechanisms of
directly inhibiting AKT will have different therapeutic outcomes
has yet to be determined.
Materials and Methods
Expression and purification of AKT1(1–443) protein
AKT1(1–443) was expressed in Trichopulsia ni High Five (BTI-
TN-5B1-4) cell line (Invitrogen, CA, USA) with a N-terminal
hexa-histidine (His) tag that is followed by a thrombin cleavage
sequence. The His-tagged AKT1(1–443) protein was enriched
from the High Five cell lysate on Talon cobalt-affinity resins
(Clontech, CA, USA) then eluted from the Talon beads in a buffer
consisting of 25 mM Tris-Cl pH 8.0, 0.3 M NaCl, 0.05% (v/v) 2-
mercaptoethanol, 100 mM imidazole, 10% (v/v) glycerol and
Complete EDTA-free protease inhibitor (Roche, IN, USA). The
Figure 6. Isozyme selectivity of allosteric inhibitors. (A) Alignment of human AKT-1 -2 and -3. Residues are shaded to illustrate amino acid
conservation. Above the sequence, N denotes residues involved in inter-domain contacts, ;denotes residues contacting Inhibitor VIII, and marks
residues involved in both inter-domain and Inhibitor VIII interactions. The arrow shows the position of the last residue in the crystallography
construct, Thr 443. (B) Close-up view of non-identical regions in the Inhibitor VIII binding pocket with coloring as follows: PH domain (orange), kinase
domain (yellow), and Inhibitor VIII (green). Residues with differences between AKT isozymes are shown in sticks and colored in cyan.
doi:10.1371/journal.pone.0012913.g006
AKT1:Allosteric Inhibitor
PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12913Figure 8. Glu 17 interacts with Arg 273 in the kinase domain. AKT1:Inhibitor VIII colored as follows: PH domain (orange), kinase domain
(yellow), Inhibitor VIII (green sticks). A salt bridge between Glu 17 and Arg 273 is observed in the closed, ‘PH-in’ conformation.
doi:10.1371/journal.pone.0012913.g008
Figure 7. PH domain conformational differences. (A) Schematic representation of the PH domain from the Inhibitor VIII bound structure
(orange) and IP4 bound (PDB code 1UNQ) structure (magenta). The most dramatic differences between the PH domains of AKT1:Inhibitor VIII and the
IP4 bound structure are in the VL3 loop containing Trp 80, which interacts with Inhibitor VIII, and loop 51–55 containing Asn 53, which interacts with
IP4. The noted regions are colored yellow in the Inhibitor VIII bound structure and cyan in the IP4 bound structure. Trp 80 and Asn 53 are shown in
stick representation. (B) Close-up view of the IP4 binding site. AKT1 PH domain (magenta) bound to IP4 (PDB code: IUNQ) is superposed on the
AKT1:Inhibitor VIII structure. AKT1:Inhibitor VIII colored as follows: PH domain (orange), kinase domain (yellow), Inhibitor VIII (green sticks). Asn 53 in
the multi-domain structure interacts with Asn 269 and is over 10 A ˚ away from the IP4 binding site. In the Inhibitor VIII structure, Arg 86 points into the
PH domain. A movement of 8 A ˚ is required for Arg 86 to bind IP4.
doi:10.1371/journal.pone.0012913.g007
AKT1:Allosteric Inhibitor
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by incubation with thrombin. The protein was further purified by
Source Q15 anion-exchange chromatography (GE Health Biosci-
ences, NJ, USA) with a linear NaCl salt gradient. Monomeric
AKT1(1–443) protein was purified via Superdex 200 size-
exclusion chromatography (GE Health Biosciences, NJ, USA)
using the final storage buffer of 25 mM Tris-Cl pH 7.5, 100 mM
NaCl, 10% glycerol and 5 mM DTT and concentrated to
approximately 10 mg/ml. All purification steps were performed
at 4uC and the final protein was stored at 280uC.
Crystallization
Crystals were grown by the vapor diffusion method. AKT1 (1–443)
at 4.7 mg/mL was incubated with Inhibitor VIII at 0.25 mM. Hanging
drops were set up in the presence of 50% (v/v) precipitant, consisting of
12.5 mM Na-acetate, 37.5 mM Na-citrate pH 5.2, 21% PEG MME
2000 at 20uC. Co-crystals usually appeared within 1–2 days.
X-ray data collection, data processing, structure solution,
crystallographic structure refinement
AKT1-Inhibitor VIII co-crystals were harvested into a solution
of 25 mM Na-acetate, 25 mM Na-citrate, 21% PEG MME 2000,
pH 5.0 and were cryoprotected with 70% harvest solution + 30%
ethylene glycol. Cryoprotected crystals were flash cooled in a
stream of dry nitrogen vapor held at 100 K. X-ray diffraction data
were collected on a Rigaku FR-E Superbright rotating anode X-
ray generator, fitted with a Cu anode and an RAXIS IV++ image
plate detector (Rigaku, TX, USA). The diffraction data were
processed using Mosflm [26] and scaled using the program Scala
[27].
The crystals belonged to space group P21 with unit cell
dimensions of a=49.31 A ˚, b=69.94 A ˚, c=61.85 A ˚, b=100.6u.
The crystal structure was solved by molecular replacement, with
all calculations performed using the program Molrep [27]. The
molecular replacement calculations were performed in two steps:
In the first step, a search model consisting of residues 147–440 of
the inactive AKT2 kinase domain (PDB code: 1MRV) was used in
a standard rotation function/translation function calculation,
resulting in a single solution with an R-factor of 0.505 (similar
searches with an active conformation of AKT1 kinase domain
failed to find a reliable solution). The quality of this molecular
replacement solution was improved slightly by brief crystallo-
graphic refinement to 2.8 A ˚ resolution in Refmac5. In the second
step, a search model consisting of residues 2–106 of the unliganded
Figure 9. Model of AKT activation and inhibition. In the cytoplasm, the ‘PH-in’ and ‘PH-out’ conformations of AKT are in equilibrium. AKT is
recruited to the plasma membrane via interactions with the products of PI3K and is subsequently phosphorylated on two sites, T308 and S473 in
AKT1, which results in kinase activation. The allosteric inhibitor stabilizes the ‘PH-in’ form of the inactive enzyme (top left); whereas the ATP-
competitive inhibitor binds to the activated form of the kinase (bottom left). Surface representations derived from the following structures: PDB code:
3CQW (active and ATP-competitive inhibitor bound kinase), PDB code: 1UNQ (membrane-bound PH domain), PDB code: 3O96 (cytoplasmic PH and
kinase domains, and membrane-bound kinase domain). Coloring as follows: kinase domain (yellow), PH domain (orange), IP4 binding residues (cyan),
phospho-T308 (red), allosteric inhibitor (green), ATP-competitive inhibitor (blue), PI3K products (violet). Phospho-S473 is not visible in these
orientations of AKT.
doi:10.1371/journal.pone.0012913.g009
AKT1:Allosteric Inhibitor
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function/phased translation function search, using phase infor-
mation calculated from the coordinates of the AKT2 kinase
domain solution. A single PH domain plus kinase domain solution
was found with an R-factor of 0.417. This combined solution was
subjected to multiple cycles of refinement in Refmac5 to 2.7 A ˚
resolution [28], followed by model rebuilding in the program O
[29]. The final round of model rebuilding was guided by the use of
simulated annealing composite omit maps followed by crystallo-
graphic refinement in CNX 2005 [30] to generate the final
molecular model.
The final structure contains all residues of AKT1 from 2–429
except for 45–48, 114–144 (the linker region), 189–198 (the aB
and aC helices) and 299–312 (the C-terminal end of the activation
loop). The model also has 21 ordered water molecules and a single
copy of Inhibitor VIII. The R-factor of the final model is 0.245
with an Rfree value of 0.307. 312 residues (98.7%) lie in the ‘‘most-
favored’’ or ‘‘additional’’ regions of the Ramachandran plot, with
2 residues (0.6%) in the ‘‘generously allowed’’ region and 2 (0.6%)
in the ‘‘disallowed’’ regions. All figures were generated using
Pymol [31].
Supporting Information
Figure S1 SDS-PAGE analysis of dissolved inactive full-length
AKT1 co-crystal with Inhibitor VIII. A, Inactive full-length AKT1
protein (,55.9 KDa) was purified to apparent homogeneity
migrated as a single protein band by SDS-PAGE analysis (data
not shown). The protein was used with AKT Inhibitor VIII to set
up crystal screens. A very small co-crystal of inactive full-length
AKT1 protein with Inhibitor VIII grew from sparse matrix screens
and was tested for protein diffraction. The crystal was dissolved in
SDS-PAGE loading buffer and analyzed in a 10% Bis-Tris
NuPAGE gel (Invitrogen) with silver stain. The dissolved crystal
revealed a faint intact AKT1 protein band which migrated slightly
slower than the 51 KDa marker, along with two major
polypeptides with calculated molecular weights around 40 and
50 KDa, estimated using standard regression equation analysis.
Other faint protein bands larger than the 64 KDa marker are
probably randomly cross-linked AKT1 formed during the
crystallization process. The 40 KDa fragment has a similar size
as AKT1 kinase domain lacking the PH domain (16 KDa), which
was is not visible on this gel. The 50 KDa fragment suggested
AKT1 truncation at the N-, the C-, or both termini. Because the
PH-domain is required for AKT1 to bind Inhibitor VIII, we
hypothesized that the stable proteolytic fragments occurred in the
AKT1/Inhibitor VIII crystal should contain an intact PH-domain
and, therefore, have a C-terminal truncation around residue 440
resulting in an AKT1 molecule lacking the hydrophobic motif
(HM). A series of C-terminal truncated AKT1 constructs around
residue 440 were made. Only AKT1(1–443) produced soluble
protein that bound to Inhibitor VIII. B, Diagrams of AKT1
domains and their corresponding molecular weights.
Found at: doi:10.1371/journal.pone.0012913.s001 (0.50 MB TIF)
Figure S2 Differential scanning fluorimetry analysis of AKT1(1–
443) and non-activated full-length AKT-1 inhibitor binding.
AKT1(1–443) thermal unfolding was monitored by the method
described by Niesen et al [18]. 1 mM of AKT1 protein in 25 mM
HEPES buffer pH 7.5 (or 10 mM MnCl2/25 mM HEPES,
pH 7.5 for samples containing AMP-PNP) was incubated with
2% DMSO (no ligand control; red circles), Inhibitor VIII (2.5, 5,
and 10 mM; light to dark blue triangles), or AMP-PNP (10, 50, and
250 mM; light to dark blue triangles) in a volume of 30 ml at room
temperature for 10 minutes. 10 ml of SYPRO Orange dye was
added to each sample at the end of the incubation. AKT1 thermal
unfolding was determined from 25 to 95uC at a temperature
ramping duration of 30 seconds/uC using a RT-PCR thermal
cycler. Fluorescence emitted by the dye upon binding to unfolded
proteins is continuously monitored by gating the excitation at
485 nm and the emission at 575 nm. Average of representative
results performed in triplicates is shown here. The bars at data
points represent standard errors of the triplicates. A, AKT1(1–443)
thermal stability in the presence of Inhibitor VIII; B, AKT1(1–
443) thermal stability in the presence of Mn-AMP-PNP.; C,
Inactive full-length AKT1 thermal stability in the presence of
Inhibitor VIII; D, Inactive full-length AKT1 thermal stability in
the presence of Mn-AMP-PNP; E, Summary of midpoint
transition temperature of thermal unfolding (Tm) and Tm changes
(DTm) of AKT1(1–443) versus inactive full-length AKT1 caused
by Inhibitor VIII. The presence of inhibitor VIII resulted in a
dose-dependent increase in Tm of AKT1(1–443), suggesting
AKT1(1–443) binds to the inhibitor and the binding stabilizes
the protein. While 10 mM inhibitor increased the Tm of both
AKT1(1–443) and the non-activated full-length AKT1 by 6–8uC,
the presence of 250 mM of the ATP analog, AMP-PNP, had no
effect on the Tm of either AKT1 compared to MnCl2 alone (red
circles in panels B and D). This indicates that AKT1(1–443), like
the inactive full-length AKT1, has a very low affinity to ATP and
its analog. The similar response between the two forms of AKT1
to Inhibitor VIII and AMP-PNP suggests that AKT1(1–443)
resembles the non-activate full-length AKT1 protein.
Found at: doi:10.1371/journal.pone.0012913.s002 (0.51 MB TIF)
Figure S3 PH domain VL3 loop structural comparison. Multi-
domain AKT1 structure VL3 loop (orange) with Inhibitor VIII
shown in green sticks; Cyan: VL3 loop of apo AKT1-PH domain
structure (1UNP); Magenta: VL3 loop of AKT1-PH domain
structure with IP4 (1UNQ). The position of Trp 80 (shown in
sticks) varies significantly between all three structures. In the
allosterically inhibited structure, the side chain of Trp 80 p-stacks
with Inhibitor VIII and its conformation appears to be strongly
affected by the inhibitor.
Found at: doi:10.1371/journal.pone.0012913.s003 (0.78 MB TIF)
Figure S4 Interactions of AKT1 residues 51–55 with the kinase
domain and Inhibitor VIII. Close-up view of an inter-domain
contact region showing the PH domain in orange, kinase domain
in yellow, and Inhibitor VIII in green sticks. The side chains for
the 51–55 loop of the PH domain are shown in orange sticks. The
interacting kinase domain residues are illustrated with yellow lines.
Each residue from 51–55 has at least one interaction with a
residue in the kinase domain and Asn 54 also interacts with
Inhibitor VIII via a water molecule. As shown in Figure 7A, this
loop assumes a dramatically different conformation in the IP4
bound structure. The extensive network of inter-domain interac-
tions plays a major role in disrupting the IP4 binding site in the
’PH-in’ conformation. Also, of note, the loop from 267–269 in
AKT1 is one residue shorter in AKT2 and AKT3; therefore these
isozymes are anticipated to have a slightly different set of inter-
domain interactions.
Found at: doi:10.1371/journal.pone.0012913.s004 (4.24 MB TIF)
Figure S5 IP4 binding residues interact with kinase domain
residues in the Inhibitor VIII structure. A, IP4 binding residues
(magenta sticks) are shown on the schematic representation of
AKT1 PH domain bound to IP4 from PDB:1UNQ. The residues
involved in directly binding IP4 were identified as Lys 14, Arg 23,
Arg 25, Asn 53, and Arg 86 [19,31] In the IP4 bound PH domain
structure, Arg 23 contacts both the 1- and 3- phosphates and Arg
25 contacts the 3-phosphate of IP4. B, AKT1:Inhibitor VIII
AKT1:Allosteric Inhibitor
PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12913structure shown in the same orientation as the PH domain in
Panel A. Coloring as follows: PH domain (orange), kinase domain
(yellow), Inhibitor VIII (green sticks). Residues in the PH domain
corresponding to those previously identified to interact with IP4
(Panel A) are shown as sticks. Kinase domain residues interacting
with Arg 23 and Arg 25 are also represented in stick form. In the
AKT1:Inhibitor VIII complex structure, Arg 23 and Arg 25
interact extensively with the kinase domain. The side chain of Arg
23 makes a polar contact to the side chain of Asp 323; whereas the
side chain of Arg 25 contacts the backbone carboxyl of both Glu
322 and Asp 323 and the side chain of Asn 324.
Found at: doi:10.1371/journal.pone.0012913.s005 (2.13 MB TIF)
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